Method for proliferation of antigen-specific T cells
AssigneeImmunicum AB
InventorsAlex Karlsson-Parra, Anna-Carin Wallgren, Bengt Andersson
Life of this patent
Estimating the term…
Abstract
The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.
Claims4
Antigen specific CD4+ and/or CD8+ T cells obtained by in vitro priming of genetically modified antigen specific CD4+ and/or CD8+ T cells suitable for administration to a patient having a tumor, wherein the priming comprises co-culturing tumor antigen receptor expressing target T cells from the patient to be treated, mature dendritic cells, anti-CD3 antibodies and lymphocytes that have been sensitized against WIC class I and/or WIC class II antigens on antigen presenting cells (APCs).
Antigen specific CD4+ and/or CD8+ T cells suitable for administration to a patient wherein said CD4+ and/or CD8+ T cells:
- have the ability to proliferate,
- no more than 40% of the cells should exhibit positive staining for Annexin-V, and/or
- express CD27 and/or CD28 at their cell surface.
Dependencies are inferred from the claim text.